Results from the Phase 3 STELLAR-303 trial, investigating zanzalintinib plus atezolizumab against regorafenib in patients with refractory colorectal cancer, were published on January 1, 2025.
Background
The STELLAR-303 trial explored atezolizumab in combination with zanzalintinib. This combination was evaluated as a potential treatment option for patients diagnosed with refractory colorectal cancer, a stage of the disease where previous standard treatments have been unsuccessful.
Trial design
The STELLAR-303 study was a randomised, open-label, phase 3 trial. It compared the combination of zanzalintinib plus atezolizumab against regorafenib in participants with refractory colorectal cancer.
What this means
The publication of the STELLAR-303 trial results means that the findings regarding zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer are now available for review by the scientific and clinical communities. While specific outcome measurements are not detailed in this summary, the trial's completion and publication are significant steps in evaluating potential new therapies for this challenging condition.
Source
The information regarding the STELLAR-303 trial was published on January 1, 2025, in The Lancet, and sourced from PubMed, an online database of biomedical literature. The publication is titled 'Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.' and is accessible via pubmed.ncbi.nlm.nih.gov.